Operations: Marksans Pharma Limited generates revenue primarily from its pharmaceutical formulations segment, amounting to ₹22.68 billion.

Marksans Pharma, a notable player in the pharmaceutical sector, has shown strong financial health with cash exceeding total debt and a reduced debt-to-equity ratio from 19.9% to 11.7% over five years. The company reported earnings growth of 21.7% last year, surpassing the industry average of 19.3%. Recent Q1 results revealed net income at INR 887.52 million, up from INR 686.58 million year-on-year, reflecting robust performance and potential for future growth through M&A activities in Europe.

• Navigate through the intricacies of Marksans Pharma with our comprehensive health report here.

• Learn about Marksans Pharma's historical performance.

Sundaram Finance Holdings

Simply Wall St Value Rating: ★★★★★☆

Overview: Sundaram Finance Holdings Limited engages in investments, business processing, and support services across India, Australia, and the United Kingdom with a market cap of ₹92.14 billion.

Operations: The company generates revenue primarily from investments (₹2.51 billion), domestic shared services (₹105.51 million), and overseas shared services (₹489.78 million).

Sundaram Finance Holdings (SFHL) has demonstrated impressive growth, with earnings surging by 114.5% over the past year, outpacing the Auto Components industry’s 20.1%. The company has a price-to-earnings ratio of 16.1x, well below the Indian market average of 34.3x, indicating potential value. Recent earnings for Q1 FY2024 showed revenue at INR 442.78 million and net income at INR 1,103.35 million compared to INR 706.72 million last year; basic EPS rose to INR 4.97 from INR 3.18.

• Click to explore a detailed breakdown of our findings in Sundaram Finance Holdings' health report.

• Assess Sundaram Finance Holdings' past performance with our detailed historical performance reports.

Seize The Opportunity

• Click through to start exploring the rest of the 470 Indian Undiscovered Gems With Strong Fundamentals now.

• Already own these companies? Bring clarity to your investment decisions by linking up your portfolio with Simply Wall St, where you can monitor all the vital signs of your stocks effortlessly.

• Take control of your financial future using Simply Wall St, offering free, in-depth knowledge of international markets to every investor.

Contemplating Other Strategies?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.

• Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.

• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include NSEI:IIFLSEC NSEI:MARKSANS and NSEI:SUNDARMHLD.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com